Explore the Agenda
7:00 am Doors Open for Registration, & Pre-Event Networking
7:50 am Organizer Opening Remarks
Opportunities & Deal Trends Following Best-in-Class Opportunity in Oncology
8:00 am Pharma Icebreaker Panel Discussion: Targeted Oncology Biologics
- Understanding what it takes for pharma to invest. What are the current budgetary considerations within pharma?
- How is pharma assessing novel technologies, and where do they place within portfolios?
- What feels differentiated in a crowded space? From pharma’s perspective, what will make something best-in-class?
Conviction to Transact in Immunology: Data or FOMO?
8:40 am Pharma Icebreaker Panel Discussion: Investing into Immune Rest, Rebalance & Reconstitution
- Which stage of development is most appealing in Immunology?
- What are the starting points, from a data package perspective, when it comes to assessing engagers or in vivo CAR-T?
- When evaluating an early-stage what level of data—whether safety, biomarkers, or efficacy—provides you with conviction that the program has true drug potential?
- Which diseases do you think are most promising for B-cell targeted therapies?
9:20 am Short Comfort Break to Arrange Organized Networking Session
9:30 am Pharma Icebreaker Tables: Accelerating Connections
- The pharma icebreaker tables running in each track create introductions between biotech and pharma
- Two weeks out from the conference, pharma will review attending biotech and biotech will review attending pharma, with both making selection to meet with companies they haven’t scheduled meetings with yet through the One-to-One Partnering Portal
- With these selections, we will build a schedule of company rotations through each pharma’s table
- Join three tables, led by three pharma, for 30 minutes each. Mixed groups rather than 1-2-1s, hear how your peers pitch themselves whilst also getting facetime with pharma yourself, first thing on day one
11:15 am Morning Break & One-to-One Partnering Meetings Open for Day One
In vivo CAR-T versus TCEs: Where Does the Future Land?
11:45 am Scientific, Operational & Economic Realities for Immune-Modulating Therapies: What Have we Learnt so Far?
- Pharma’s reflections on recent in vivo CAR-T and TCE deals, what data was valuable when clinical data was minimal?
- Overlapping and diverging advantages of TCEs to in vivo CAR-T, including depth and durability of response.
- Debating clinical-adjacent innovations in delivery across viral vectors and LNPs and their application in immunology versus oncology
Is on-Target Toxicity a Bad Thing? The Balance Between Efficacy & Worsening Toxicity
12:15 pm Tumor Selectivity Strategies Across Multispecifics, TCEs, & ADCs: What Have we Learnt so Far?
- Engineering conditional activation through masking and pre-dosing in TCEs and ADCs
- Discussing dual-target and multispecific approaches
- Applying induced proximity to ADC specificity to substantially change the behaviour of an ADC
12:45 pm Lunch Break & Networking Opportunity
Where do DACs fit in 2026/27 Portfolios? From Preclinical Promise to First-in-Human
2:00 pm Increasing the Therapeutic Index of a Small Molecule as Precision ADCs: What Have we Learnt so Far?
- Designing DACs to be a more targeted to oncogenic drivers versus traditional small molecule inhibitors
- Discussing initial proof-of-concept case studies for DACs
- Collaboration potential between antibody engineering and protein degradation companies
2:30 pm Presentation Session One: Showcase Your Science
Present your company’s slides by securing a 15-minute presentation slot in front of the
attending audience.
What is this session?
At the intersection of innovative research and business conversations, this forum facilitates the
pitching of biotech pipelines and platforms to attending pharma and investors.
How does this session work?
As you register, secure one of the 15-minute presentation slots available in this presentation
session and position your differentiation as part of the conference line-up. We will add your
talk to this brochure and on our website to showcase your differentiation in the best light and
share your corporate summary with all attendees as part of pre- and post-event content, to drive
interest and follow-up in your session.
Who can present?
Those developing in-house pipeline or platform technology, without any additional service
provider capabilities, such as contract research or manufacturing.
2.00 Presentation by SKYMAB Biotherapeutics
2.15 Presentation by Bicycle Therapeutics
2.30 Presentation by Rapafusyn
3:30 pm Afternoon Break & One-to-One Partnering Meetings Restart
4:15 pm 2025/26 Deal-Making Highlights: How Did They Happen?
- Representing examples of successful deal-making and successful management of alliances to foster future deals, what are the learnings?
- Sharing how early-stage programs can successfully navigate the “show me data” barrier with pharma, and the activation barrier to licencing technologies between equal sized biotech
- Debating recent regulatory and emerging technology shifts, and how these will shape licensing deals for the discussed modalities
5:00 pm Drinks Reception
Connect more casually at the end of day one drinks reception. Enjoy an informal networking with all attending colleagues, to follow up with contacts from other partnering initiatives, catch those you haven’t already run into, and meet with old connections again in-person. Deliberately timed ahead of key events in the business development calendar, use this as an opportunity to become front-of-mind, and start conversations going into the Fall calendar.